|
|
Article: Dynavax Presents Positive TOLAMBA Phase 2/3 Results at AAAAI Meeting.
- Article from:
- PR Newswire
- Article date:
- March 6, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Safety and Efficacy Endpoints Achieved Following Single, Short Course of Therapy
BERKELEY, Calif., March 6 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation presented positive results from a well-controlled, two-year, multi-center Phase 2/3 clinical trial of TOLAMBA(TM), a ragweed allergy immunotherapeutic, in an oral presentation at the 2006 annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in Miami, Florida. Data showing safety and statistical significance relative to the efficacy endpoints in the study were presented by the principal investigator for the trial, Dr. William W. Busse, MD, Professor of Medicine, University ...